Literature DB >> 26227254

Metabolism and Disposition of Prescription Opioids: A Review.

A Z DePriest, B L Puet, A C Holt, A Roberts, E J Cone.   

Abstract

Opioid analgesics are commonly prescribed for acute and chronic pain, but are subject to abuse. Consequently, toxicology testing programs are frequently implemented for both forensic and clinical applications. Understanding opioid metabolism and disposition is essential for assessing risk of toxicity and, in some cases, providing additional information regarding risk of therapeutic failure. Opioids significantly metabolized by the cytochromeP450 (CYP450) enzyme system maybe subjectto drug-drug interactions, including codeine, hydrocodone, oxycodone, fentanyl, meperidine, methadone, buprenorphine, and tramadol. CYP2D6 metabolism is polymorphic, and pharmacogenetic testing has been investigated for codeine, tramadol, oxycodone, and hydrocodone. CYP2B6 pharmacogenetic testing of methadone may reduce the risk of cardiac toxicity associated with the S-enantiomer. Opioids metabolized primarily by uridine 5'-diphospho-glucuronsyltransferase (UGT) enzymes include morphine, hydromorphone, dihydrocodeine, oxymorphone, levorphanol, and tapentadol. Parent and metabolite disposition is described for blood, oral fluid, and urine. Parent drug is most commonly detected in blood and oral fluid, whereas metabolites typically predominate in urine. Oral fluid/blood ratios exceed 1 for most opioids, making this an excellent alternative matrix for testing of this drug class. Metabolites of codeine, hydrocodone, and oxycodone are commercially available, and knowledge of metabolism is necessary for correct interpretation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26227254

Source DB:  PubMed          Journal:  Forensic Sci Rev        ISSN: 1042-7201


  16 in total

1.  Change in prescription habits after federal rescheduling of hydrocodone combination products.

Authors:  Susan Seago; Adam Hayek; Jessica Pruszynski; Megan Greene Newman
Journal:  Proc (Bayl Univ Med Cent)       Date:  2016-07

Review 2.  Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism.

Authors:  Elyse M Cornett; Michelle A Carroll Turpin; Allison Pinner; Pankaj Thakur; Tamizh Selvan Gnana Sekaran; Harish Siddaiah; Jasmine Rivas; Anna Yates; G Jason Huang; Anitha Senthil; Narjeet Khurmi; Jenna L Miller; Cain W Stark; Richard D Urman; Alan David Kaye
Journal:  Curr Oncol Rep       Date:  2020-02-06       Impact factor: 5.075

3.  The effect of SARS-CoV-2 on the prescribing of antimicrobials and analgesics by NHS general dental practitioners in England.

Authors:  Nikolaus O A Palmer; Noha Seoudi
Journal:  Br Dent J       Date:  2021-01-21       Impact factor: 1.626

4.  Effects of CYP2C19 variants on the metabolism of tapentadol in vitro.

Authors:  Ren-Ai Xu; Ping Fang; Zhize Ye; Mingming Han; Jian-Ping Cai; Guo-Xin Hu
Journal:  Iran J Basic Med Sci       Date:  2022-05       Impact factor: 2.532

Review 5.  Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.

Authors:  Taha Ahmad; Monica A Valentovic; Gary O Rankin
Journal:  Biochem Pharmacol       Date:  2018-02-16       Impact factor: 5.858

6.  A genome-wide association study of tramadol metabolism from post-mortem samples.

Authors:  Frank R Wendt; Anna-Liina Rahikainen; Jonathan L King; Antti Sajantila; Bruce Budowle
Journal:  Pharmacogenomics J       Date:  2019-04-11       Impact factor: 3.550

7.  Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.

Authors:  Natalie Reizine; Keith Danahey; Emily Schierer; Ping Liu; Merisa Middlestadt; Jenna Ludwig; Tien M Truong; Xander M R van Wijk; Kiang-Teck J Yeo; Monica Malec; Mark J Ratain; Peter H O'Donnell
Journal:  Oncologist       Date:  2021-09-19

8.  CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort.

Authors:  Concetta Dagostino; Massimo Allegri; Valerio Napolioni; Simona D'Agnelli; Elena Bignami; Antonio Mutti; Ron Hn van Schaik
Journal:  Pharmgenomics Pers Med       Date:  2018-10-24

Review 9.  An update on drug-drug interactions between antiretroviral therapies and drugs of abuse in HIV systems.

Authors:  Nuti Desai; Leah Burns; Yuqing Gong; Kaining Zhi; Asit Kumar; Nathan Summers; Santosh Kumar; Theodore J Cory
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-08-31       Impact factor: 4.481

Review 10.  Pharmacogenomics of oxycodone: a narrative literature review.

Authors:  Nelly N Umukoro; Blessed W Aruldhas; Ryan Rossos; Dhanashri Pawale; Janelle S Renschler; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2021-03-17       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.